ftInvstr
MAXIND · Healthcare ₹151.3 +1.59% Mkt Cap ₹799 Cr

MAXIND

Healthcare Medical Care Facilities
₹151.3
+1.59% today · 30d -2.38%
as of 2026-11-09
Price · Daily Candles
“MAXIND grapples with severe losses as quarterly profit plunges, prompting rights issue amid FII/Promoter stake cuts.”
MAXIND reported a Q4 2025 net loss of ₹43 Cr, with annual revenue declining by 29.22% to ₹145 Cr in FY25. The company's ROCE stands at a substantial -24.0%, and it trades at a Price-to-Book of 1.7 despite ongoing financial challenges.
BULL CASE
+Quarterly revenue for Q4 2025 showed a 24.06% YoY increase to ₹43 Cr, indicating some recovery.
+Forecasts for Free Cash Flow (FCF) show moderate to strong predictions, with one-year FCF rankings ranging from neutral (0.638) to strong (0.664) across different timeframes.
+Despite negative operating profit in Q4 2025, operating profit margin improved by 8.84% QoQ.
BEAR CASE
−MAXIND recorded a net loss of ₹43 Cr in Q4 2025 and an annual net loss of ₹140 Cr in FY25, alongside a significantly negative ROCE of -24.0%.
−The stock price has seen a 19.11% decline over the last year and is currently trading 37.47% off its 52-week high of ₹241.57.
−Promoter holding decreased by 0.07% to 49.82% and FII holding decreased by 0.01% to 7.07% QoQ ending March 2026.
−ML predictions for Sales growth are weak, with 1-year sales growth ranks ranging from 0.348 to 0.391.
−The company's P/B ratio of 1.7 highlights potential overvaluation relative to its book value of ₹89.4, particularly given its negative profit margin of -80.64%.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-09-30
REVENUE
₹87 Cr
+92.18% YoY
NET PROFIT
₹-22 Cr
OPM
-11.96%
+38.37pp YoY
EPS
₹-4.02
Intrinsic value · DCF: N/A — Company is currently free-cash-flow negative (-18.3% of mktcap). DCF assumes a going concern generating positive cash flow; a meaningful intrinsic value can only be computed once FCF turns positive. Use the Strategy Fit and ML sections instead.
◇ Sector Position
MAXIND's negative ROCE of -24.0% contrasts sharply with sector peers like APOLLOHOSP (ROCE 20.26%) and NH (ROCE 22.72%), and its Price-to-Sales of 4.33 sits below the PE ratios of profitable peers such as APOLLOHOSP (PE 82.13) and MAXHEALTH (PE 67.07).
PEERPEROCE %
MAXIND—-24.0
APOLLOHOSP82.1320.26
MAXHEALTH67.0714.44
FORTIS94.2613.4
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
39
SCORE / 100
Overall
6-axis composite of the sections below.
Performance UNDERPERFORMER 20
Valuation — —
Growth STRONG 72
Profitability LOW 5
Technicals WEAK 47
Risk MODERATE 50
Key Stats
P/B
1.7
52W HIGH
₹220.0
OFF HIGH
-31.23%
MKT CAP
₹799 Cr
◉ Active Signals
MACDNeutral0.1165
RSI(14)Neutral50.79
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold MAXIND and at what entry.

Sign up freeSign in